Your browser is no longer supported. Please, upgrade your browser.
Settings
SPHS Sophiris Bio, Inc. daily Stock Chart
SPHS [NASD]
Sophiris Bio, Inc.
Index- P/E- EPS (ttm)-0.19 Insider Own0.85% Shs Outstand30.57M Perf Week-5.13%
Market Cap22.39M Forward P/E- EPS next Y-0.45 Insider Trans0.00% Shs Float29.96M Perf Month-6.60%
Income-5.80M PEG- EPS next Q-0.10 Inst Own7.70% Short Float5.96% Perf Quarter-31.54%
Sales- P/S- EPS this Y21.50% Inst Trans-3.68% Short Ratio13.99 Perf Half Y-65.93%
Book/sh-0.01 P/B- EPS next Y-58.10% ROA-40.20% Target Price4.56 Perf Year-80.67%
Cash/sh0.29 P/C2.49 EPS next 5Y- ROE582.10% 52W Range0.71 - 3.84 Perf YTD-11.75%
Dividend- P/FCF- EPS past 5Y30.50% ROI- 52W High-80.92% Beta2.86
Dividend %- Quick Ratio2.00 Sales past 5Y- Gross Margin- 52W Low2.59% ATR0.04
Employees6 Current Ratio2.00 Sales Q/Q- Oper. Margin- RSI (14)29.77 Volatility4.19% 5.38%
OptionableYes Debt/Eq- EPS Q/Q29.40% Profit Margin- Rel Volume0.63 Prev Close0.74
ShortableYes LT Debt/Eq- EarningsMar 20 AMC Payout- Avg Volume127.70K Price0.73
Recom2.20 SMA20-5.36% SMA50-17.02% SMA200-51.81% Volume80,067 Change-1.09%
Feb-14-18Reiterated Maxim Group Buy $6 → $5
Mar-13-17Initiated Rodman & Renshaw Buy $6
Sep-15-16Initiated ROTH Capital Buy $8
Aug-30-16Initiated Piper Jaffray Overweight $7
Aug-10-16Reiterated Maxim Group Buy $4 → $6
Dec-18-14Downgrade Stifel Buy → Hold $7
Oct-24-14Initiated Maxim Group Buy $10
Sep-10-13Initiated Stifel Buy $9
Jun-14-19 07:21AM  Some Sophiris Bio (FRA:BFF1) Shareholders Have Taken A Painful 79% Share Price Drop Simply Wall St.
May-14-19 09:30AM  SPHS: EMA Guidance on Phase 3 Clinical Trial for Topsalysin Expected in 2Q19 Zacks Small Cap Research
May-09-19 04:05PM  Sophiris Bio Reports First Quarter 2019 Financial Results PR Newswire
Apr-02-19 04:05PM  Sophiris Bio to Present at Two Upcoming Investor Conferences PR Newswire
Mar-29-19 11:45AM  SPHS: Awaiting Regulatory Guidance for Topsalysin Phase 3 Study Zacks Small Cap Research
Mar-13-19 04:05PM  Sophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate Highlights PR Newswire
Dec-19-18 09:20AM  SPHS: Ready to Move Topsalysin into Phase 3 for Localized Clinically Significant Prostate Cancer Zacks Small Cap Research -11.22%
Dec-17-18 08:00AM  Sophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer Trial PR Newswire -40.58%
Dec-06-18 03:42AM  Does Sophiris Bio Inc (FRA:BFF1) Have A Volatile Share Price? Simply Wall St.
Nov-20-18 11:00AM  SPHS: Data from Second Administration of Topsalysin in Phase 2b Trial Anticipated Before End of 2018 Zacks Small Cap Research
Nov-16-18 07:30AM  Report: Exploring Fundamental Drivers Behind HC2, Pangaea Logistics Solutions, Sophiris Bio, Acacia Research, JAKKS Pacific, and LeMaitre Vascular New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-15-18 04:05PM  Sophiris Bio to Present at the Piper Jaffray Healthcare Conference PR Newswire +6.63%
Nov-13-18 04:05PM  Sophiris Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights PR Newswire
Sep-25-18 08:00AM  Sophiris Bio to Present at the Cantor Global Healthcare Conference PR Newswire
Sep-14-18 08:00AM  Sophiris Bio Extends the Interest Only Period under its Loan and Security Agreement PR Newswire
Aug-30-18 02:30PM  SPHS: Patient Death in Phase 2b Trial Unlikely Related to Topsalysin Treatment Zacks Small Cap Research
08:00AM  Todays Research Reports on Stocks to Watch: Opiant Pharmaceuticals and Sophiris Bio ACCESSWIRE
Aug-29-18 04:30PM  Sophiris Bio to Present at the H.C. Wainwright 20th Annual Global Investment Conference PR Newswire +24.61%
08:00AM  Sophiris Bio Updates on Phase 2b Localized Prostate Cancer Trial PR Newswire
Aug-21-18 09:30AM  SPHS: Ready to Advance Topsalysin into Registration Studies Zacks Small Cap Research +5.74%
Aug-14-18 04:05PM  Sophiris Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights PR Newswire
Jul-12-18 09:30AM  SPHS: Interim Data Reported for P2b Study of Topsalysin in Localized Prostate Cancer Zacks Small Cap Research
Jun-27-18 08:00AM  Todays Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Sophiris ACCESSWIRE
Jun-26-18 08:00AM  Today's Research Reports on Trending Tickers: Sophiris Bio and Achaogen ACCESSWIRE +34.82%
Jun-25-18 09:02AM  Sophiris Bio shares plummet 46% on news of patient death in trial for prostate cancer drug MarketWatch -40.27%
08:37AM  Sophiris Bio Reports Top-Line Interim Safety and Biopsy Findings For its Phase 2b Clinical Trial of Topsalysin in Localized Prostate Cancer PR Newswire
Jun-11-18 07:08AM  Want To Invest In Sophiris Bio Inc (NASDAQ:SPHS)? Heres How It Performed Lately Simply Wall St.
May-21-18 10:00AM  SPHS: Countdown to Release of Topline Data for Phase 2b Study of Topsalysin in Prostate Cancer at end of 2Q18 Zacks Small Cap Research
May-16-18 08:10AM  Benzinga's Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings Benzinga
May-14-18 04:01PM  Sophiris Bio Reports First Quarter 2018 Financial Results and Key Corporate Highlights PR Newswire +6.92%
May-06-18 09:07AM  Loss-Making Sophiris Bio Inc (NASDAQ:SPHS) Expected To Breakeven Simply Wall St.
Mar-26-18 10:15AM  SPHS: Topline Results from Phase 2b Study of Topsalysin at end of 2Q18 Zacks Small Cap Research
Mar-21-18 04:05PM  Sophiris Bio Reports Fourth Quarter and Full Year 2017 Financial Results and Key Corporate Highlights PR Newswire
Mar-15-18 04:05PM  Sophiris Bio to Present at 17th Annual Needham Healthcare Conference PR Newswire
Dec-27-17 09:00AM  Sophiris Bio to Participate in the 10th Annual Biotech Showcase Conference PR Newswire
Dec-11-17 08:00AM  Sophiris Bio Announces Complete Enrollment in Phase 2b Topsalysin Study of Localized Prostate Cancer PR Newswire +8.47%
Nov-27-17 08:00AM  Sophiris Bio to Participate in the 29th Annual Piper Jaffray Healthcare Conference PR Newswire
Nov-21-17 05:49PM  Is Sophiris Bio Incs (SPHS) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Nov-20-17 01:00PM  SPHS: First Dosing in Phase 2b Trial of Topsalysin in Prostate Cancer Almost Complete; Data in 1H18 Zacks Small Cap Research
Nov-09-17 04:05PM  Sophiris Bio Reports Third Quarter Financial Results and Key Corporate Highlights PR Newswire
Oct-02-17 08:00AM  Sophiris Bio Provides Enrollment Update on Topsalysin Phase 2b Study in Localized Prostate Cancer PR Newswire
Sep-13-17 04:05PM  Sophiris Bio Secures up to $10 Million in Term Loans from Silicon Valley Bank PR Newswire
Aug-17-17 08:00AM  Sophiris Bio to Present at the Rodman & Renshaw 19th Annual Global Investment Conference PR Newswire
Aug-15-17 11:30AM  SPHS: Phase 2b Trial of Topsalysin in Prostate Cancer Underway Zacks Small Cap Research
Aug-10-17 05:15PM  Sophiris Bio Reports Second Quarter Financial Results and Key Corporate Highlights PR Newswire
Jun-23-17 04:05PM  Sophiris Bio Added to Russell Microcap Index PR Newswire
Jun-08-17 08:00AM  Sophiris Bio Announces that the First Patient Has Been Dosed in Phase 2b Study of Topsalysin in Patients with Clinically Significant Localized Prostate Cancer PR Newswire
May-23-17 04:05PM  Sophiris Bio Provides Update on Phase 2b Study of Topsalysin in Localized Prostate Cancer PR Newswire
May-18-17 04:00PM  SPHS: Dosing of Patients in Phase 2b Trial of Topsalysin in Prostate Cancer to Initiate Soon Zacks Small Cap Research
May-15-17 04:05PM  Sophiris Bio Reports First Quarter Financial Results and Key Corporate Highlights PR Newswire
07:00AM  Sophiris Bio Presents Topsalysin Data from Phase 2a Proof-of-Concept Study in Localized Prostate Cancer at 112th American Urological Association (AUA) Meeting PR Newswire
Mar-29-17 04:05PM  Sophiris Bio to Present at 16th Annual Needham Healthcare Conference PR Newswire
04:00PM  SPHS: Phase 2b Trial of Topsalysin in Prostate Cancer Underway Zacks Small Cap Research
Mar-27-17 09:00AM  Sophiris Bio Reports Fourth Quarter and Full Year 2016 Financial Results and Key Corporate Highlights PR Newswire
Mar-23-17 04:05PM  Topsalysin Data from Successful Phase 2a Localized Prostate Cancer Study to be Presented at the 32nd European Association of Urology Congress PR Newswire
Mar-13-17 08:39AM  Coverage initiated on Sophiris Bio by Rodman & Renshaw
Mar-06-17 04:01PM  Sophiris Bio to Present at 29th Annual ROTH Conference PR Newswire
Jan-30-17 04:00PM  Sophiris Bio to Webcast Live Presentation at BetterInvesting's Virtual Investor Conference PR Newswire
04:00PM  Sophiris Bio to Webcast Live Presentation at BetterInvesting's Virtual Investor Conference CNW Group
02:16PM  Life Sciences & Healthcare Investor Conference & Webinar: Nasdaq and OTCQX Companies Present February 2nd PR Newswire
Dec-16-16 01:42PM  How Key Technology, Inc. (KTEC) Stacks Up Against Its Peers at Insider Monkey
Dec-01-16 08:47AM  Sophiris Bio, Inc. :SPHS-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016 Capital Cube
08:47AM  Sophiris Bio, Inc. :SPHS-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
Nov-22-16 08:00AM  Sophiris Bio to Present at 28th Annual Piper Jaffray Healthcare Conference PR Newswire
Nov-09-16 04:11PM  Sophiris Bio reports 3Q loss
04:01PM  Sophiris Bio Reports Third Quarter 2016 Financial Results and Key Business Highlights PR Newswire
Oct-10-16 04:00PM  Sophiris Bio to Present at the 2016 BIO Investor Forum PR Newswire
Oct-06-16 01:25PM  Three Biotech Companies With Large Upside Potential Benzinga
Sep-20-16 12:18PM  Sophiris Bio, Inc. :SPHS-US: Earnings Analysis: Q2, 2016 By the Numbers : September 20, 2016
Sep-15-16 10:43AM  Sophiris Bio (SPHS) Stock Coverage Initiated at Roth Capital
Sep-12-16 12:00PM  SPHS: Initiating on Sophiris Bio, Inc.; Developing Novel Treatments for Urologic Conditions
Sep-04-16 10:40AM  5 Speculative Biotech Analyst Stocks Under $10 With Massive Upside at 24/7 Wall St.
Aug-30-16 08:55AM  Top Analyst Upgrades and Downgrades: Apple, BHP Billiton, Broadcom, McDonalds, Sophiris, Tech Data and More at 24/7 Wall St.
Aug-26-16 04:01PM  Sophiris Bio Closes Underwritten Public Offering PR Newswire
Aug-25-16 08:58PM  Sophiris Bio Inc. (NASDAQ:SPHS): Sabby Capital Reports Large New Stake at Insider Monkey
Aug-23-16 12:27PM  Look Out Below! Whats the Deal With These 5 Falling Stocks? at Insider Monkey
10:11AM  Sophiris Bio's stock plunges to pace Nasdaq losers after discounted share offering at MarketWatch
10:05AM  Sophiris Bio (SPHS) Stock Tumbles on Public Offering
09:00AM  Sophiris Bio Prices Public Offering of Common Shares and Warrants PR Newswire
Aug-22-16 05:01PM  Sophiris Bio shares tank on secondary stock offering at MarketWatch
04:01PM  Sophiris Bio Announces Proposed Public Offering of Common Shares and Warrants PR Newswire
Aug-09-16 04:01PM  Sophiris Bio Reports Second Quarter 2016 Financial Results and Key Business Highlights PR Newswire
Jul-23-16 06:55PM  eBay, AMD Head the List of Nasdaq Stocks Hitting 52-Week Highs Friday at Insider Monkey
Jun-14-16 09:48AM  These Small Cap Stocks Are On The Move
Jun-10-16 11:40AM  Sophiris Soars on Positive Phase 2 Results
10:19AM  Fridays Most Buzzworthy Stocks: Antero, Valeant, Southwestern Energy, More at Insider Monkey
08:13AM  Sophiris Bio's stock more than doubles after prostate cancer treatment's successful test results at MarketWatch
07:50AM  Sophiris Bio Up 113% After Successful Results From Phase 2a Trial Of Topsalvsin In Localized Prostate Cancer
Jun-09-16 05:29PM  Sophiris shares rally on promising cancer treatment study at MarketWatch
04:00PM  Sophiris Bio Reports Successful Results from Completed Phase 2a Study of Topsalysin in Localized Prostate Cancer PR Newswire
May-16-16 04:01PM  Sophiris Bio Reports First Quarter 2016 Financial Results and Key Business Highlights PR Newswire
May-12-16 04:01PM  Sophiris Bio Engages Oppenheimer & Co. to Advise on Strategic Opportunities PR Newswire
May-11-16 04:01PM  Sophiris Bio Inc. Announces Closing of Public Offering of $5,000,000 PR Newswire
May-06-16 05:30PM  Sophiris Bio Inc. to Raise Approximately $5 Million Through At-the-Market Offering PR Newswire
May-05-16 04:00PM  Sophiris Bio To Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as a Late Breaking Poster During the 111th American Urological Association Annual Meeting PR Newswire
Apr-28-16 04:00PM  Sophiris Bio to Present at Bloom Burton & Co. Healthcare Investor Conference PR Newswire
Mar-23-16 04:16PM  Sophiris Bio Reports Fourth Quarter and Full Year 2015 Financial Results and Key Business Highlights at noodls
04:01PM  Sophiris Bio Reports Fourth Quarter and Full Year 2015 Financial Results and Key Business Highlights PR Newswire
Feb-02-16 04:01PM  Sophiris Bio to Present at BIO CEO & Investor Conference PR Newswire
Jan-29-16 02:00PM  Sophiris Bio Inc Review of Topsalysin Clinical Data Call scheduled for 2:00 pm ET today
Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WOODS RANDALL EPresident & Chief Exec OfficerSep 19Buy2.6310,00026,33910,000Sep 20 01:08 PM